Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
2001
Dexrazoxane and Doxorubicin Resistance in Leukaemia Cells
publication
Evidence: high
Author Information
Author(s): Sargent J M, Williamson C J, Yardley C, Taylor C G, Hellmann K
Primary Institution: Haematology Research, Pembury Hospital, Pembury, Kent TN2 4QJ, UK
Hypothesis
Dexrazoxane may interfere with the mechanism involved in the emergence of multidrug resistance (MDR).
Conclusion
Dexrazoxane delays the development of doxorubicin resistance in K562 cells, allowing for continued response to treatment.
Supporting Evidence
- Dexrazoxane combined with doxorubicin leads to a significant decrease in doxorubicin cardiotoxicity.
- There was a significant increase in median survival time for patients with advanced breast cancer responsive to FAC.
- Doxorubicin resistance was not induced in the presence of dexrazoxane for several months.
- The expression of functional P-glycoprotein was delayed after the addition of dexrazoxane.
Takeaway
Dexrazoxane helps cancer patients by preventing their bodies from becoming resistant to a common chemotherapy drug.
Methodology
Resistance to doxorubicin was induced in K562 cells, and the effects of dexrazoxane on drug sensitivity and P-glycoprotein expression were measured.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website